A Study of the Acceptability and Performance of Wearables for Atrial Fibrillation Screening in Older Adults
NCT ID: NCT04715555
Last Updated: 2025-04-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
130 participants
OBSERVATIONAL
2023-02-02
2025-05-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Atrial fibrillation (AF) is an irregular heart rhythm which causes a five-fold increase in the risk of stroke. Approximately one in ten people aged over 70 have AF. If AF is recognised then the risk of stroke can be reduced by taking tablets regularly. AF can be difficult to recognise as it can occur without symptoms and only intermittently. Consequently, AF is not recognised in many people, meaning they live with an increased risk of stroke. Therefore, it is important to find ways to identify AF more reliably.
Recently, wearable devices have been developed which could be useful for identifying AF. Several devices can monitor heart activity in daily life, including wristbands, smart watches and chest patch monitors. The aim of this study is to assess the acceptability and performance of wearables for use in AF screening in older adults.
The primary objective is to determine the feasibility of measuring inter-beat-intervals using a wristband. The secondary objectives are:
(i) to determine the acceptability of wearables; (ii) to determine the acceptability of the screening approach; (iii) to assess the performance of wearables for acquiring signals; (iv) to assess the performance of signal processing algorithms; and (v) to assess the performance of wearables for AF screening.
\--- Who can participate?
Selected people who have previously participated in the SAFER Programme can participate in this study. The Investigators will invite previous SAFER Programme participants to also participate in this study, aiming to enrol 65 without AF, and 65 with AF.
\--- What does the study involve?
Participants will be asked to wear three devices for seven days: Two wristbands (like watches), and one chest patch (like a plaster). These devices will collect measurements of their heart's activity. The Investigators will also ask participants to tell them how they found wearing the devices by completing a questionnaire. The Investigators will compare how participants found wearing each device, and how accurately each device identifies AF.
\--- What are the possible benefits and risks of participating?
There will be no direct benefit to participants, although this research is intended to benefit future patients like them. Some participants may experience irritation or redness whilst wearing a chest patch - participants will be advised that if this occurs then they should remove it straightaway.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Atrial Fibrillation Health Literacy and Information Technology Trial
NCT04075994
Atrial Fibrillation Screening With a Smartphone Device and iECG Application
NCT02534532
Sensitivity and Specificity of a Mobile Lead-one ECG Like Device for the Detection of Atrial Fibrillation (AF)
NCT03524625
A Study of Prolonged Electrocardiographic Monitoring in Patients With Heart Failure in Sinus Rhythm or Atrial Fibrillation
NCT02707744
SmartWATCHes for Detection of Atrial Fibrillation
NCT02956343
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The University of Cambridge.
\--- Study procedures
Participants will be asked to:
1. Consent: Participants will be asked to confirm their consent to take part by posting the enclosed consent form to the Investigators in a prepaid envelope.
2. Device delivery: The Investigators will send participants the devices, a detailed instruction leaflet, and a questionnaire.
3. Training: The Investigators will explain to participants how to wear and use the devices over the telephone, referring to the instruction leaflet.
4. Wear the devices: Participants will be asked to wear the devices for seven days, going about their daily life as normal. The devices are waterproof. If a participant has chest hair then they will need to shave a small area for the chest-patch to stick to. The Investigators will ask participants to use the watch four times each day to record heart activity for 30 seconds. Participants will be asked to plug in a small hub which will send information from the devices. The Investigators will telephone participants during the study to check for any problems.
5. Questionnaire: Participants will be asked to complete a questionnaire on the devices after wearing them.
6. Return devices: At the end, the Investigators will telephone participants and arrange a courier to pick up the devices and questionnaire from their home (which the Investigators will arrange and pay for).
Participants will be given an instruction leaflet with further details of each step.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atrial Fibrillation
Participants with a diagnosis of atrial fibrillation (AF) who exhibited AF in previous AF screening (as part of the SAFER Programme).
Electrocardiogram monitoring
Continuous monitoring using a wearable, single-lead electrocardiography (ECG) device affixed to the chest.
Electrocardiogram recording
Intermittent electrocardiogram (ECG) recordings taken using a wearable device on the wrist.
Photoplethysmogram monitoring
Photoplethysmogram monitoring using a wearable device on the wrist.
Feedback questionnaire
A questionnaire to collect feedback on participants' experiences of wearing the devices.
Non-Atrial Fibrillation
Participants without a diagnosis of atrial fibrillation (AF) who have previously undergone AF screening (as part of the SAFER Programme).
Electrocardiogram monitoring
Continuous monitoring using a wearable, single-lead electrocardiography (ECG) device affixed to the chest.
Electrocardiogram recording
Intermittent electrocardiogram (ECG) recordings taken using a wearable device on the wrist.
Photoplethysmogram monitoring
Photoplethysmogram monitoring using a wearable device on the wrist.
Feedback questionnaire
A questionnaire to collect feedback on participants' experiences of wearing the devices.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Electrocardiogram monitoring
Continuous monitoring using a wearable, single-lead electrocardiography (ECG) device affixed to the chest.
Electrocardiogram recording
Intermittent electrocardiogram (ECG) recordings taken using a wearable device on the wrist.
Photoplethysmogram monitoring
Photoplethysmogram monitoring using a wearable device on the wrist.
Feedback questionnaire
A questionnaire to collect feedback on participants' experiences of wearing the devices.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 65 years or over
* Lives in private accommodation
* Willing and able to give informed consent
Exclusion Criteria
* Has a chest wound
* Previous reaction to, or known allergy to ECG electrodes or silicone
* Receiving palliative care
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
City, University of London
OTHER
University of Leicester
OTHER
University of Cambridge
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Peter Charlton
British Heart Foundation Research Fellow
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter H Charlton, MEng, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Cambridge
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Cambridge
Cambridge, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FS/20/20/34626
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
20/EM/0255
Identifier Type: OTHER
Identifier Source: secondary_id
IRAS 283812
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.